Evidence Question

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) reduce cardiovascular risk?

Short answer

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to reduce cardiovascular risk.

Evidence at a glance

Evidence strength: Emerging Evidence
Supporting research: 3 studys
Randomized trials: 3 trials

Why do we say this?

Across 3 randomized trials, the evidence showed an effect on cardiovascular risk with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).

Explore the evidence

Open in Evidence Explorer View Cardiovascular Risk

Supporting research

3 published studys

Finerenone reduces heart and kidney event risk in CKD and T2D
Finerenone improves heart failure outcomes in patients with diabetes.
Finerenone reduces hypokalaemia risk in CKD and T2D patients.